Nanjing Vcare Helps Nanjing Chiatai Tianqing's Anti-tumor New Drug CXA03 to Obtain the Clinical Approval

2022-12-30

Recently, CXA03, a Class 1 anti-tumor new drug developed by Nanjing Chiatai Tianqing, a strategic cooperation partner of Nanjing Vcare, obtained the implied permission for drug clinical trials from the National Medical Products Administration. This project is another successful innovative drug project in cooperation with Nanjing Chiatai Tianqing after Nanjing Vcare helped Nanjing Chiatai Tianqing's Class 1 new drug, an AKT-targeted inhibitor, obtain the clinical approval in August 2021.

Nanjing Vcare gave full play to the advantages of the whole-industry-chain and whole-life-cycle R&D services of CRO/CDMO, and provided the whole-process services of "intermediates + active pharmaceutical ingredients + preparations" for Nanjing Chiatai Tianqing's CXA03 project, including the R&D and supply of key starting materials, the technical development and quality research of active pharmaceutical ingredients and preparations, the research on API salt forms and crystal forms, non-clinical sample supply, GMP production and technical handover, and document writing. From the start of the project to the completion of the IND (Investigational New Drug) application, Nanjing Vcare only took 14 months, ensuring the project progress and research quality and helping it smoothly obtain the implied permission for drug clinical trials.

Prev

Nanjing Vcare Was Successfully Selected as an "Innovative Small and Medium-sized Enterprise in Nanjing"

Next

Nanjing Vcare Assisted Lizhu Pharmaceutical to Obtain the Production Approval Letter of Pantoprazole Sodium for Injection